Lupin unveils generic version of CellCept in US

Lupin Ltd's Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche’s CellCept.

Mumbai: Pharma major Lupin Limited (Lupin) recently announced the launch of Mycophenolate Mofetil Capsules USP, 250 mg. Lupin’s alliance partner Concord Biotech Limited (Concord) had received approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche’s CellCept.

Mycophenolate Mofetil Capsules are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.

Also Read: Lupin ropes in Jon Stelzmiller to head US speciality business

Mycophenolate Mofetil Capsules USP, 250 mg, had annual sales of approximately USD 53 million in the U.S. (IQVIA MAT August 2019).

For the financial year ended 31^st March 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively.

Based in Mumbai, Lupin is a player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAI D space and holds a global leadership position in the Anti-TB segment.

Also Read: Lupin unveils a generic version of Viagra in the US